04:12
+7 C°
Traffic jam:   0
$
74.1373
89.5060

Companies

Description

Alexion Pharmaceuticals Inc. is an American pharmaceutical company best known for its development of Soliris, a drug used to treat the rare disorders atypical hemolytic uremic syndrome (aHUS) and paroxysmal nocturnal hemoglobinuria (PNH). The company is also involved in immune system research related to autoimmune diseases. It employs around 2,400 people worldwide. In February 2016, the company held the dedication ceremony for its new headquarters in New Haven, Connecticut, not far from the company's starting point in the same city.

In September 2017, Alexion announced it would be moving its headquarters to Boston, Massachusetts, in mid-2018.

In December 2020, the company was acquired by AstraZeneca for a reported $39 billion.

History

Alexion Pharmaceuticals was founded in 1992 at Science Park in New Haven, Connecticut by Steven Squinto and Leonard Bell. Bell served as the company's CEO until 2015. In 2000, Alexion moved its headquarters from New Haven to Cheshire, Connecticut. Alexion moved back to New Haven following the completion of New Haven's Downtown Crossing project in December 2015.

Since 2006, Alexion has been a supporter of healthcare research and quality studies at Duke University for aspirin and Clopidogrel (trade name Plavix).

Alexion received U.S. Food and Drug Administration (FDA) approval for Soliris in 2007. It was initially approved to treat paroxysmal nocturnal hemoglobinuria, a rare blood disorder. In 2010, there was an outbreak of hemolytic-uremic syndrome caused by Enterohaemorrhagic Escherichia coli (EHEC) in Germany. Soliris was considered a treatment option because of its effectiveness in treating Atypical hemolytic uremic syndrome, an illness similar to the one caused by the EHEC infection.

In April 2011, Alexion was added to the NASDAQ-100, a group composed of the 100 largest non-financial stocks traded on the NASDAQ; with a market value of US$8.5 billion it replaced Genzyme Corporation.

In April 2015, Bell was replaced as CEO by David Hallal. In 2016, the company became a member of the Pharmaceutical Research and Manufacturers of America (PhRMA).

In December 2016, Alexion's board of directors announced new leadership. David Brennan, a current board member, became interim CEO. David Anderson, formerly the CFO of Honeywell, was appointed CFO, replacing Vikas Sinha.[15] In March 2017, Alexion named Ludwig N. Hantson as its new CEO.

In September 2017, Alexion announced that it would be closing its Smithfield, RI manufacturing facility.

Rating GlobalNY.biz

Take place
general
№216
general
Take place
area
№13
In rating
Healthcare
area

Discussion

NEW YORK COMPANIES


New York business portal GlobalNY.biz includes a huge directory of organizations operating in New York. Here you can easily find all the necessary information about the company. The organization card contains a full info page with a detailed description of the company's activities, logo, contact details and a link to the organization's official website. The reader can also immediately familiarize himself with the staff of the company, see the latest press releases and news block, and also see what line of the rating the company occupies. The rating of a member of the GlobalNY.biz business portal is calculated based on the number of mentions in the New York news and posted press releases containing information about the organization's activities and its achievements. You can also rise in the rating by publishing vacancies, as well as the number of registered persons. At the same time, company representatives can independently see how many times the company's card has been viewed on GlobalNY.biz, as well as promptly correct the information.
We pay special attention to the multifunctionality of the "Companies" section. For your convenience, there is a search box, as well as an industry heading.
New York Business Portal is always up-to-date database of New York enterprises!
Alena Potapova

Development Director